How did ICUI's revenue and expenses trend in Q4 2024?

ICU Medical's revenue for Q4 2024 was $629.81 million, compared to $589.1 million in the same period of the previous year. This indicates a growth in revenue, which can be attributed to increases across all product lines, including Consumables, Infusion Systems, and Vital Care. However, there was no corresponding data on expenses for Q4 2024.

1. Revenue Growth: ICU Medical reported a 6.5% increase in revenue from $553.3 million in Q3 2023 to $589.1 million in Q3 2024. This growth was driven by rises in revenue from all product lines, with Consumables revenue increasing to $264.9 million, Infusion Systems revenue rising to $159.8 million, and Vital Care revenue reaching $164.5 million.
2. Financial Performance: The company's gross profit for Q3 2024 was $204.9 million, with a gross margin of 34.8%. This represents an improvement from the previous year's gross profit of $183.9 million and a gross margin of 33.2%. Adjusted diluted earnings per share were $1.59, slightly up from $1.57 in the same period last year.
3. Challenges and Outlook: Despite the revenue growth, ICU Medical posted a GAAP net loss of $(33.0) million, or$(1.35) per diluted share, in Q3 2024, compared to a net income of $7.2 million, or $0.30 per diluted share, in the same period of the previous year$. The company updated its fiscal year 2024 guidance, projecting a GAAP net loss in the range of (130) to $(122) million and a GAAP diluted loss per share between$(5.28) and $(4.98), with adjusted EBITDA guidance set at a range of $355 million to $365 million and adjusted diluted earnings per share expected to be between $5.40 and $5.70.

In conclusion, ICU Medical experienced revenue growth in Q4 2024, driven by increases in sales across all product lines, but faced challenges in terms of net profitability. The company's updated guidance for fiscal year 2024 reflects a projected net loss, which may indicate ongoing financial challenges despite revenue growth.